Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chloroquine, TTFields, Temozolomide and Radiation for Glioblastoma
NCT04397679Phase 1Terminated
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Aug 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of chloroquine in glioblastoma (GBM), sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoint: Proportion of patients who develop grade 3 or higher dermatitis at 3 months. Started Aug 2021; status: terminated.
02
Drugs
chloroquine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04397679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04397679.